X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for X4 Pharmaceuticals, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:03.989 Please stand by, your program is about to begin. 00:00:05.010 -- 00:00:10.771 Greetings and welcome to this X4 Pharmaceuticals call and webcast. 00:00:10.771 -- 00:00:14.652 At this time, all participants are in a listen-only mode. 00:00:14.652 -- 00:00:18.973 A question and answer session will follow the formal presentation. 00:00:18.973 -- 00:00:23.014 As a reminder, this conference call is being recorded. 00:00:23.014 -- 00:00:29.035 It is now my pleasure to introduce your host, Dan Ferry, from LifeSci Advisors. 00:00:29.035 -- 00:00:31.335 Please begin. 00:00:31.974 -- 00:00:34.556 Thank you, Operator, and good morning, everyone. 00:00:34.556 -- 00:00:38.938 Thank you for joining us today for this special earnings call, during which X4 will focus 00:00:38.938 -- 00:00:44.062 on providing a business update and, importantly, data and results 00:00:44.062 -- 00:00:50.364 from its now-completed Phase 2 study of Mavericks 4 and chronic neutropenia. 00:00:51.146 -- 00:00:55.269 As a reminder, on today's call, the company will be making forward-looking statements 00:00:55.269 -- 00:00:59.542 regarding regulatory and product development and commercialization plans. 00:00:59.542 -- 00:01:03.425 as well as research activities and financial projections. 00:01:03.425 -- 00:01:06.568 These statements are subject to risks and uncertainties that may cause actual results 00:01:06.568 -- 00:01:09.291 to differ from those forecasted. 00:01:09.291 -- 00:01:14.275 Discretion of these risks can be found in X4's most recent filings with the SEC, including 00:01:14.275 -- 00:01:18.779 this year's Form 10-K, which was filed on March 21, 2024, 00:01:18.779 -- 00:01:23.803 and in the company's Form 10-Q for the third quarter, which 00:01:23.803 -- 00:01...